Explore: Thromboxane A2

Thromboxane A2 (TXA2) is a type of thromboxane that is produced by activated platelets during hemostasis and has prothrombotic properties: it stimulates

Thromboxane is a member of the family of lipids known as eicosanoids. The two major thromboxanes are thromboxane A2 and thromboxane B2. The distinguishing

its preferred endogenous ligand thromboxane A2. The gene responsible for directing the synthesis of the thromboxane receptor, TBXA2R, is located on human

inhibitors. Low-dose aspirin use irreversibly blocks the formation of thromboxane A2 in platelets, which inhibits platelet aggregation during the lifetime

phospholipase-A2, then brought to either the cyclooxygenase pathway or the lipoxygenase pathway. The cyclooxygenase pathway produces thromboxane, prostacyclin

is a precursor in the formation of leukotrienes, prostaglandins, and thromboxanes. Together with omega−3 fatty acids and other omega−6 fatty acids, arachidonic

99.1) that is responsible for biosynthesis of prostanoids, including thromboxane and prostaglandins such as prostacyclin, from arachidonic acid. A member

reticulum membrane protein catalyzes the conversion of prostaglandin H2 to thromboxane A2, a potent vasoconstrictor and inducer of platelet aggregation, and also

counteracts any increase in cytosolic calcium levels that would result from thromboxane A2 (TXA2) binding (leading to platelet activation and subsequent coagulation)

Thromboxane B2 (TXB2) is an inactive metabolite/product of thromboxane A2. It is almost completely cleared in the urine. It itself is not involved in